PPARG and pulmonary arterial hypertension: Legchenko et al. found that the PPAR-γ agonist pioglitazone reversed pulmonary hypertension through fatty acid oxidation mainly associated with lipid metabolism and disturbed mitochondrial morphology/function in right ventricular failure and pulmonary vascular hypertension49.